



Company Contact:
Richard Gabriel
CEO and President
941 366-3400
-or-
Ron Stabiner
The Wall Street Group, Inc.
212-888-4848

FOR IMMEDIATE RELEASE:

**WALL STREET REPORTER AIRS INTERVIEW
WITH DNAPRINT CEO RICHARD GABRIEL**

SARASOTA, Fla., March 20, 2006 -- DNAPrint genomics, Inc. (OTCBB: DNAG) today announced that President and Chief Executive Officer Richard Gabriel is the subject of an interview and webcast with the Wall Street Reporter magazine.

During the interview, which can be accessed on the Company's web site at www.dnaprint.com and <http://www.wallstreetreporter.com/linked.php?id=16659>. Mr. Gabriel discussed the role of the Company in the development of "theranostics" – drug/genetic test combinations to help ensure patients receive the appropriate medicine and proper dosage based on their genetic constitution, increasing efficacy and reducing side effects.

"We have been focusing on licensing and technologies," Mr. Gabriel stated. "One lead compound is being evaluated by NIDA, which is the National Institute on Drug Abuse, and we have two other compounds which we've identified for attention deficit as well as depression, which is a new mechanism."

Mr. Gabriel also noted that one of the projects the Company is currently working on is the development of new diagnostic tests to better define and manage the complications of diabetes more effectively, particularly microvascular damage.

DNAPrint Genomics is also working under a licensing agreement with a well-known and prestigious East Coast medical center to clinically develop and commercially implement a "Super EPO", a more potent, longer-lasting form of the anemia treatment drug erythropoietin.

About DNAPrint Genomics, Inc.

DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

(MORE)

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

###